ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 442

Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels

Gregory J. Challener1, Jonathan D. Jones2, B. JoNell Hamilton1, Gilles Boire3, Artur José de Brum-Fernandes4, Pierre Cossette5, Patrick Liang3, Ariel Masetto6, Nathalie Carrier7, Henri A. Ménard8 and William F.C. Rigby9, 1Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, 2Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, 3Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Médecine, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 5Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 6Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 7Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 8Rheumatology, Research Institute of the McGill University Health Center, Montreal, QC, Canada, 9Rheumatology; Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, citrullinated vimentin and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by anti-citrullinated protein antibodies; ACPA) to homocitrullination of lysines.  Since 2011, humoral responses to homocitrullinated proteins (subsequently referred to as anti-carbamylated protein antibodies; ACarP Ab) have been reported in both early and established seropositive RA.  We analyzed the relationship of serum/plasma levels of ACarP Ab to several clinical and serologic parameters, using both established and early RA cohorts.

Methods: Carbamylation of fetal calf sera was performed as previously described [1].  Patients with established RA (n=212) were recruited at Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA).  Serum and/or plasma ACarP Ab, anti-Sa Ab, CXCL13, rheumatoid factor (RF), ACPA (specifically, anti-CCP2 Ab) and total IgG were measured by ELISA.  Seropositivity (positive for RF, anti-CCP or both) and C-Reactive Protein level were determined by the clinical lab.  A confirmatory analysis was performed using samples from early RA patients included in the Sherbrooke, QC (Canada) cohort.  T-test, ANOVA and correlation analysis were utilized to evaluate relationships between variables.  63 healthy controls were also evaluated for levels of ACarP Ab.

Results: Among seropositive patients in the Dartmouth cohort (n=164), 46.6% exhibited elevated levels of ACarP Ab.  ACarP Ab titers correlated with levels of ACPA (p=0.004) and IgM-RF (p=0.04).  Seropositive patients in the early RA Sherbrooke cohort (n=173) displayed similar trends; 38.2% had elevated ACarP Ab levels, and ACarP Ab titer was highly associated with levels of ACPA  (p=0.005) and weakly associated with IgM-RF (p=0.06).  The relationship of ACarP Ab levels with baseline clinical parameters (age, DAS28-CRP, erosions, etc.) was either weak or absent in both cohorts.  Intriguingly, we observed a highly significant correlation between anti-Sa status and ACarP Ab titer among seropositive patients in the Sherbrooke cohort (p<0.0002), with 47.9% of anti-Sa-positive patients harboring elevated levels of ACarP Ab versus 25.4% of anti-Sa-negative patients.  This observation led us to test seropositive RA samples in the Dartmouth cohort for anti-Sa status; once again, a highly significant relationship was observed (p<0.000001); 62.6% of anti-Sa-positive patients showed elevated ACarP Ab levels versus 26.9% of anti-Sa-negative patients.

Conclusion: This is the first investigation of ACarP Ab levels in a population of established RA patients in the US, comparing it with an early RA Canadian cohort.  A large proportion of each seropositive RA cohort exhibited elevated levels of ACarP Ab (38.2-46.6%).  Most compellingly, we identified a strong relationship between levels of ACarP Ab and anti-Sa reactivity that raises the mechanistic question of how antibody responses to carbamylated proteins and citrullinated vimentin (Sa) are linked in vivo.

1. Shi, J., et al., Autoantibodies Recognizing Carbamylated Proteins Are Present in Sera of Patients with Rheumatoid Arthritis and Predict Joint Damage. PNAS, 2011. 108(42): p. 17372-77.


Disclosure:

G. J. Challener,
None;

J. D. Jones,
None;

B. J. Hamilton,
None;

G. Boire,
None;

A. J. de Brum-Fernandes,
None;

P. Cossette,
None;

P. Liang,
None;

A. Masetto,
None;

N. Carrier,
None;

H. A. Ménard,
None;

W. F. C. Rigby,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-carbamylated-protein-antibody-levels-are-elevated-in-seropositive-rheumatoid-arthritis-and-correlate-with-anti-sacitrullinated-vimentin-antibody-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology